Literature DB >> 27904742

Rifampicin and isoniazid plasma concentrations in relation to adverse reactions in tuberculosis patients: a retrospective analysis.

L Aït Moussa1, O El Bouazzi2, S Serragui3, D Soussi Tanani4, A Soulaymani5, R Soulaymani6.   

Abstract

OBJECTIVE: High concentrations of antituberculosis (anti-TB) drugs can be associated with many adverse drug reactions (ADRs). The objective of this study was to examine the plasma concentrations of rifampicin (RMP) and isoniazid (INH) in patients with and without ADRs.
METHODS: Concentration monitoring data of patients treated with anti-TB drugs were retrospectively analyzed from 2009 to 2011. RMP and INH plasma concentrations were measured 2 and 3 h after drug administration respectively using high-performance liquid chromatography.
RESULTS: A total of 54 out of 120 patients have experienced ADRs to anti-TB drugs. The median concentrations [interquartile range (IQR)] obtained in patients with and without ADRs were 6.7 mg/l (3.7-9.9) and 5.6 mg/l (2.9-8.6) (p = 0.56) for RMP and 4.3 mg/l (2.3-5.3) and 3.1 mg/l (1.7-4.8) (p = 0.04) for INH, respectively. Related median doses (IQR) were 8.7 mg/kg (8.0-10.0) and 8.6 mg/kg (6.5-9.9) (p = 0.42) for RMP and 4.8 mg/kg (4.3-5.0) and 4.0 mg/kg (2.8-5) (p < 0.01) for INH, respectively. Concentrations above the expected range in patients with and without ADRs were not reached for RMP, but were 76% and 65% for INH, respectively. Correlation between concentrations and doses has not been established for RMP or INH. In addition, high INH concentrations showed no association with sex, age, liver injury or renal or diabetes.
CONCLUSIONS: High INH concentrations were common in patients with and without ADRs whereas RMP concentrations were low or within the normal range in most patients. Further studies are required to assess the association between high INH concentrations and the occurrence of ADRs.

Entities:  

Keywords:  adverse drug reactions; drug concentrations; isoniazid; rifampicin

Year:  2016        PMID: 27904742      PMCID: PMC5117155          DOI: 10.1177/2042098616667704

Source DB:  PubMed          Journal:  Ther Adv Drug Saf        ISSN: 2042-0986


  30 in total

Review 1.  N-acetyltransferase.

Authors:  D A Evans
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

2.  Correlation between steady-state plasma concentration of antituberculous drugs and age, inclusion of rifampicin in the treatment regimen, adverse drug reactions and other clinical parameters.

Authors:  J Woo; C Chan; R Chan; W Cheung; K Or; K Chan
Journal:  J Med       Date:  1995

3.  Stability of rifampin in plasma: consequences for therapeutic monitoring and pharmacokinetic studies.

Authors:  C Le Guellec; M L Gaudet; S Lamanetre; M Breteau
Journal:  Ther Drug Monit       Date:  1997-12       Impact factor: 3.681

4.  Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients.

Authors:  N Ben Fredj; R Gam; E Kerkni; A Chaabane; Z Chadly; N Boughattas; K Aouam
Journal:  Pharmacogenomics J       Date:  2016-04-19       Impact factor: 3.550

Review 5.  Therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Charles A Peloquin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Adverse reactions to antituberculosis drugs in in-hospital patients: Severity and risk factors.

Authors:  Ana Sofia Vilariça; Nelson Diogo; Mota André; Jaime Pina
Journal:  Rev Port Pneumol       Date:  2010 May-Jun

7.  Study of adverse drug reactions caused by first line anti-tubercular drugs used in directly observed treatment, short course (DOTS) therapy in Western Nepal, Pokhara.

Authors:  Anupa Khadka Chhetri; Anupa Khatri Chhetri; Archana Saha; Sharat Chandra Verma; Subish Palaian; Pranaya Mishra; Pathiyil Ravi Shankar
Journal:  J Pak Med Assoc       Date:  2008-10       Impact factor: 0.781

8.  [Microanalysis of plasma isoniazid and acetylisoniazid by high performance liquid chromatography].

Authors:  C Lacroix; G Laine; J P Goulle; J Nouveau
Journal:  J Chromatogr       Date:  1984-04-13

9.  Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity.

Authors:  A Satyaraddi; T Velpandian; S K Sharma; S Vishnubhatla; A Sharma; A Sirohiwal; G K Makharia; S Sinha; A Biswas; S Singh
Journal:  Int J Tuberc Lung Dis       Date:  2014-02       Impact factor: 2.373

10.  Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction.

Authors:  Maxwell T Chirehwa; Roxana Rustomjee; Thuli Mthiyane; Philip Onyebujoh; Peter Smith; Helen McIlleron; Paolo Denti
Journal:  Antimicrob Agents Chemother       Date:  2015-11-09       Impact factor: 5.191

View more
  4 in total

1.  The Isoniazid Metabolites Hydrazine and Pyridoxal Isonicotinoyl Hydrazone Modulate Heme Biosynthesis.

Authors:  Christopher Trent Brewer; Lei Yang; Anne Edwards; Yan Lu; Jonathan Low; Jing Wu; Richard E Lee; Taosheng Chen
Journal:  Toxicol Sci       Date:  2019-03-01       Impact factor: 4.849

2.  Very-Rapidly Dissolving Printlets of Isoniazid Manufactured by SLS 3D Printing: In Vitro and In Vivo Characterization.

Authors:  Tahir Khuroo; Eman M Mohamed; Sathish Dharani; Canberk Kayalar; Tanil Ozkan; Mathew A Kuttolamadom; Ziyaur Rahman; Mansoor A Khan
Journal:  Mol Pharm       Date:  2022-06-01       Impact factor: 5.364

3.  Analysis of adverse drug events in pulmonary Mycobacterium avium complex disease using spontaneous reporting system.

Authors:  Takuya Ozawa; Ho Namkoong; Risako Takaya; Yusuke Takahashi; Koichi Fukunaga; Yuki Enoki; Kazuaki Taguchi; Junko Kizu; Kazuaki Matsumoto; Naoki Hasegawa
Journal:  BMC Infect Dis       Date:  2022-06-29       Impact factor: 3.667

4.  Fast and Simple LC-MS/MS Method for Rifampicin Quantification in Human Plasma.

Authors:  Žane Temova Rakuša; Robert Roškar; Anita Klančar Andrejc; Tina Trdan Lušin; Nataša Faganeli; Iztok Grabnar; Aleš Mrhar; Albin Kristl; Jurij Trontelj
Journal:  Int J Anal Chem       Date:  2019-02-03       Impact factor: 1.885

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.